A Phase I Dose Escalation Study of Daily x 3 Intravenous SJG-136 in Patients With Advanced Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 21 Apr 2014
At a glance
- Drugs SG 2000 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 20 Oct 2009 Planned end date changed from 1 Sep 2006 to 1 Feb 2011 as reported by ClinicalTrials.gov.
- 02 Jun 2008 Final results presented at the American Society of Clinical Oncology (ASCO) 2008.
- 02 Jun 2008 Status changed from in progress to completed as reported in an Ipsen media release.